Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
British Journal of Dermatology2014Vol. 172(1), pp. 244–252
Citations Over TimeTop 1% of 2014 papers
Abstract
Ustekinumab has a significantly longer drug survival than the anti-TNF-α agents. Switching from one biologic to another is associated with an impairment of drug survival. Preventing loss of efficacy is a major area of medical need in the biologic therapy of psoriasis and the strategies that improve drug survival should be further investigated.
Related Papers
- → Psoriasis(2010)2 cited
- Expression and function of serum soluble CD147 in patients with psoriasis(2014)
- The detection and clinical significance of the PDEs activities in psoriasis patients(2012)
- A Case of Photosensitive Psoriasis Initiated by Sun Exposure(2002)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)